Drug Trial Radar · NCT05350969
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
294
Actual
Start
Jul 11, 2022
Primary completion
Sep 26, 2024
Study completion Mar 17, 2025
Sponsor
- Lead sponsor
- Cardior Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Apr 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction (MI). This study consists of a screening period (to occur at least 3 days after MI diagnosis), a 6-month double-blind period, and a 6-month extension period with the End of Study (EOS) Visit at Day 360/Month 12. Two dosages of CDR132L will be tested against placebo on their effects on patients, who just had a heart attack in addition to standard care. The aim of the study is to show that CDR132L is safe and effective to improve heart failure in such patients.
Conditions
- Myocardial Infarction, Acute
- Heart Failure, Left Sided
Interventions
CDR132LDrug
CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
Placebo to CDR132LDrug
Placebo to CDR132L
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in LVESVI (Left Ventricular End-systolic Volume Index) at Month 6Time frame: Baseline (Day 1), Month 6
Locations
49 sites in 8 countries. Site status is shown where the registry gives one.
Institut klinicke a experimentalni mediciny
Prague, Czechia
Všeobecná fakultní nemocnice v Praze
Prague, Czechia
St. Marien-Krankenhaus Ahaus
Ahaus, Germany
Herzzentrum Dresden Universitätsklinik
Dresden, Germany
Helios Klinikum Erfurt
Erfurt, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
Klinikum Ludwigshafen
Ludwigshafen, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
"Alexandra" General Hospital of Athens
Athens, Greece
"Attikon" General University Hospital
Athens, Greece
General University Hospital of Patras "Panagia i Voitheia"
Pátrai, Greece
Semmelweis University
Budapest, Hungary
Jeroen Bosch Ziekenhuis (JBZ) (Hieronymus Bosch Hospital) - locatie Den Bosch
's-Hertogenbosch, Netherlands
Deventer Ziekenhuis
Deventer, Netherlands
Slingeland Ziekenhuis
Doetinchem, Netherlands
Gelderse Vallei Ziekenhuis
Ede, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
St. Jansdal Ziekenhuis
Lelystad, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
Ikazia Ziekenhuis
Rotterdam, Netherlands
D & A Research B.V.
Sneek, Netherlands
Gelre Ziekenhuizen
Zutphen, Netherlands
Polsko Amerykanskie Kliniki Serca
Kędzierzyn-Koźle, Poland
Specjalistyczna Poradnia Kardiologiczna i Nadcisnienia Tetniczego
Kielce, Poland
Krakowski Szpital Specjalistyczny im. Jana Pawla II
Krakow, Poland
Gabinet Internistyczno-Kardiologiczny Jacek Nowak
Libiąż, Poland
NZOZ SALUS JZ Peruga
Lodz, Poland
One wojskowy Szpital Kliniczny w Lublinie
Lublin, Poland
Medicome Sp. z o.o.
Oświęcim, Poland
Wojewódzki Szpital im. Sw. Ojca Pio w Przemyslu
Przemyśl, Poland
NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog
Sopot, Poland
Wojewodzki Szpital Zespolony
Torun, Poland
Spec.Szpital im.dr Sokolowskiego
Wałbrzych, Poland
Investigational Site
Wroclaw, Poland
Hospital Universitari Germans Trias i Pujol
Badalona, Spain
Hospital de la Santa Creu I Sant Pau
Barcelona, Spain
Hospital Universitario San Cecilio
Granada, Spain
Hospital Universitario La Paz
Madrid, Spain
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.